MSDC-0602K (Azemiglitazone potassium), a PPARγ -sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC 50 of 18.25 μM. MSDC-0602K modulates the mitochondrial pyruvate carrier (MPC). MSDC-0602K can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance. MSDC-0602K, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide.

Diabetic db/db and MS-NASH mice are treated with MSDC-0602K by oral gavage, Liraglutide by s.c. injection, or combination MSDC-0602K + Liraglutide. This combination treatment may be an effective therapeutic strategy for diabetes and non-alcoholic steatohepatitis (NASH). Animal Model: Five-week-old male db/db mice on C57BL/6J background and age/sex-matched db/+ control mice[1]Dosage: 30 mg/kg MSDC-0602K; 0.2 mg/kg Liraglutide (obtained from MedChemExpress; HY-P0014) Administration: MSDC-0602K gavage daily, Liraglutide s.c. injection every other day, or combined MSDC-0602K+ Liraglutide Result: MSDC-0602K corrected glycemia and reduced insulinemia when given alone, or in combination with Liraglutide. However, MSDC-0602K + Liraglutide combination more significantly improved glucose tolerance and liver histology.

1314533-27-1

C19H17KNO5S

410.51

MSDC-0602K;Azemiglitazone potassium;MSDC-0602K

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years